NCT00340678View on ClinicalTrials.gov

Renoprotection in Early Diabetic Nephropathy in Pima Indians

PHASE3CompletedINTERVENTIONAL
Enrollment

170

Participants

Timeline

Start Date

August 31, 1995

Primary Completion Date

May 31, 2012

Study Completion Date

March 31, 2014

Conditions
Diabetic Nephropathy
Interventions
DRUG

Losartan

Treatment with losartan began at 50 mg daily, with the dose increasing to 100 mg daily after 1 week if symptomatic hypotension did not develop.

DRUG

Placebo

Treatment with placebo corresponding to each dose of losartan.

Trial Locations (1)

85014

NIDDK, Phoenix, Phoenix

All Listed Sponsors
lead

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

NCT00340678 - Renoprotection in Early Diabetic Nephropathy in Pima Indians | Biotech Hunter | Biotech Hunter